Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

TARS
Tarsus Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close
Sep 15, 2025 3:59:55 PM EDT
49.63USD+0.547%(+0.27)867,474
49.63Bid   49.68Ask   0.05Spread
Pre-market
Sep 15, 2025 8:48:30 AM EDT
49.75USD+0.790%(+0.39)100
After-hours
Sep 15, 2025 4:11:30 PM EDT
49.59USD-0.081%(-0.04)3,311
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 4, 2022
09:00AM EST  Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation   GlobeNewswire Inc
Dec 21, 2021
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2021   Benzinga
06:07AM EST  HC Wainwright & Co. Initiates Coverage On Tarsus Pharmaceuticals with Buy Rating, Announces Price Target of $40   Benzinga
Nov 23, 2021
04:30PM EST  Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following virtual investor conferences:   GlobeNewswire Inc
10:17AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021   Benzinga
09:41AM EST  Oppenheimer Initiates Coverage On Tarsus Pharmaceuticals with Outperform Rating, Announces Price Target of $55   Benzinga
Nov 9, 2021
05:38PM EST  Tarsus Pharmaceuticals Q3 EPS $(0.76) Up From $(3.71) YoY, Sales $1.24M   Benzinga
Nov 4, 2021
09:46AM EDT  Tarsus Pharmaceuticals, Inc. Presents Data From Two Pioneering Studies On The Prevalence And Impact Of Demodex Blepharitis At The American Academy Of Optometry 2021 Annual Meeting   Benzinga
Nov 2, 2021
06:20PM EDT  Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference Nov. 8   Benzinga
Oct 8, 2021
04:42AM EDT  Raymond James Maintains Strong Buy on Tarsus Pharmaceuticals, Raises Price Target to $65   Benzinga
Aug 12, 2021
09:04AM EDT  Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries   GlobeNewswire Inc
Aug 4, 2021
05:40PM EDT  Tarsus Pharmaceuticals Q2 EPS $0.29   Benzinga
Jul 26, 2021
09:59AM EDT  Tarsus Pharma Late Saturday Highlighted Presentation Of New Saturn-1 Trial Data, Titan Real-World Prevalence Study Results At American Society of Cataract and Refractive Surgery Meeting   Benzinga
Jul 24, 2021
06:00PM EDT  New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving 0.5 mites per lash and 93% improving by at least one collarette grade   GlobeNewswire Inc
Jul 7, 2021
04:05PM EDT  Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg   GlobeNewswire Inc
Jun 29, 2021
07:28AM EDT  Raymond James Maintains Strong Buy on Tarsus Pharmaceuticals, Raises Price Target to $50   Benzinga
Jun 22, 2021
06:00AM EDT  Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James   GlobeNewswire Inc
Jun 21, 2021
03:27PM EDT  Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Lydall Shares Spike Higher   Benzinga
12:37PM EDT  Mid-Day Market Update: Crude Oil Rises 1.5%; Tarsus Pharmaceuticals Shares Slide   Benzinga
07:33AM EDT  Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study   Benzinga
06:10AM EDT  Tarsus Pharma Says Saturn-1 Phase 2b/3 Trial Of TP-03 Met All Primary And Secondary Endpoints   RTTNews
06:04AM EDT  Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis; Co. Reports 'Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints'   Benzinga
06:00AM EDT  Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no treatment-related discontinuations, demonstrating the potential of TP-03 to treat Demodex blepharitis, a disease with no FDA-approved therapies   GlobeNewswire Inc
Jun 18, 2021
04:05PM EDT  Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast   GlobeNewswire Inc
Jun 16, 2021
04:16PM EDT  Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease   Benzinga
04:16PM EDT  More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms   GlobeNewswire Inc
May 24, 2021
04:05PM EDT  Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual   GlobeNewswire Inc
May 11, 2021
04:22PM EDT  Tarsus Pharmaceuticals Q1 EPS $0.47 Up From $(0.74) YoY, Sales $33.43M   Benzinga
04:05PM EDT  Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July   GlobeNewswire Inc
May 6, 2021
04:52PM EDT  UPDATE: Tarsus Says Topline Data From Saturn-1 Trial Expected In Jul. 2021   Benzinga
04:52PM EDT  Tarsus Pharma Reports Initiation Of Saturn-2 Pivotal Phase 3 Trial Evaluating Safety, Efficacy Of TP-03 For Treatment Of Demodex Blepharitis   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
04:14PM EDT  Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance Of Investigational New Drug Application For TP-05 For Lyme Disease Prevention   Benzinga
04:05PM EDT  Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention   GlobeNewswire Inc
May 3, 2021
04:08PM EDT  Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans   GlobeNewswire Inc
Apr 27, 2021
04:05PM EDT  Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities   GlobeNewswire Inc
Mar 31, 2021
04:19PM EDT  Tarsus Pharmaceuticals Announces A Strategic Partnership With LianBio In March 2021 For TP-03 In Greater China Provides Tarsus With $70M Expected During The Next 12 Months   Benzinga
04:05PM EDT  Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021   GlobeNewswire Inc
Mar 30, 2021
07:14AM EDT  Tarsus Pharma Partners With LianBio For TP-03 In Greater China For Eye Diseases   Benzinga
Mar 29, 2021
04:19PM EDT  Tarsus Pharmaceuticals And LianBio Announce A Strategic Partnership To Develop And Commercialize Its TP-03 In China For The Treatment Of Demodex Blepharitis And Meibomian Gland Disease   Benzinga
04:08PM EDT  Tarsus Pharmaceuticals And LianBio Announce Strategic Partnership To Develop And Commercialize TP-03 In Greater China For Treatment Of Demodex Plepharitis And Meibomian Glad Disease   Benzinga
04:05PM EDT  Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership   GlobeNewswire Inc
Jan 19, 2021
08:30AM EST  Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as   GlobeNewswire Inc
Jan 7, 2021
09:24AM EST  Tarsus Pharmaceuticals, Inc. Appoints Dianne   GlobeNewswire Inc
Jan 5, 2021
05:00PM EST  Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual   GlobeNewswire Inc
Dec 23, 2020
07:06AM EST  Tarsus Pharma Announces Type C Meeting With FDA Regarding NDA Submission Requirements For TP-03   RTTNews
07:06AM EST  Tarsus Pharma Reports Type C Meeting With FDA Related To New Drug Application Submission Requirements For TP-03   Benzinga
07:00AM EST  Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA   GlobeNewswire Inc
Dec 21, 2020
07:00AM EST  Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell   GlobeNewswire Inc
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Nov 19, 2020
03:24PM EST  Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of   GlobeNewswire Inc
Nov 13, 2020
07:35PM EST  Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual   GlobeNewswire Inc
Nov 10, 2020
09:31AM EST  Benzinga's Top Upgrades, Downgrades For November 10, 2020   Benzinga
08:30AM EST  B of A Securities Initiates Coverage On Tarsus Pharmaceuticals with Buy Rating, Announces Price Target of $33   Benzinga
08:29AM EST  Jefferies Initiates Coverage On Tarsus Pharmaceuticals with Buy Rating, Announces Price Target of $35   Benzinga
08:27AM EST  Ladenburg Thalmann Initiates Coverage On Tarsus Pharmaceuticals with Buy Rating, Announces Price Target of $42   Benzinga
08:15AM EST  Raymond James Initiates Coverage On Tarsus Pharmaceuticals with Strong Buy Rating, Announces Price Target of $39   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Oct 22, 2020
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
Oct 20, 2020
04:05PM EDT  Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public   GlobeNewswire Inc
08:17AM EDT  The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger   Benzinga
Oct 16, 2020
10:36AM EDT  Tarsus Pharmaceuticals Shares Open For Trade At $16.20; IPO Priced At $16/Share   Benzinga
08:02AM EDT  Tarsus Pharmaceuticals Shares Expected To Open For Trade Today, IPO Priced At $16.00/Share   Benzinga
Oct 15, 2020
09:05PM EDT  Tarsus Pharma Prices IPO Of 5.50 Mln Shares At $16.00/shr   RTTNews
08:35PM EDT  Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public   GlobeNewswire Inc
Oct 11, 2020
06:35PM EDT  IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC